NCT06427668 · Phase 2 · ACTIVE NOT RECRUITING
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
This trial is testing a drug called SPG302 against a placebo in adults who already have mild-to-moderate Alzheimer's. Researchers are looking at safety, side effects, how the body processes the drug, and whether it affects symptoms. It is a Phase 2 trial, which tests early safety and whether it may work. It is not proven or approved.
You may qualify if
- Age 45-85
- Diagnosis of mild to moderate AD
- Clinical laboratory values within normal range or \< 1.5 times ULN
- If receiving AD-specific treatment, have been on stable dose for ≥ 3 months prior to first dose of study drug.
- Life expectancy of >2 years
- Able and willing to provide written informed consent
You're excluded if
- Any physical or psychological condition that prohibits study completion
- Known cardiac disease
- Active or history of malignancy in the past 5 years
- Serious infection that will not be resolved by first day of study intervention.
- History of clinically significant CNS event or diagnosis in the past 5 years.
- Acute illness within 30 days of Day 1
- History of suicidal behavior or suicidal ideation
- History of chronic alcohol use or substance abuse in the last 5 years
- HIV, hepatitis B and/or hepatitis C positive
- Vaccines within 14 days
- Receipt of investigational products within 30 days
- Blood donation within 30 days
- Pregnant or breastfeeding
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-08-17